Annual report pursuant to Section 13 and 15(d)

Commitments and Contingencies (Details Narrative)

v3.20.1
Commitments and Contingencies (Details Narrative) - USD ($)
12 Months Ended
Oct. 08, 2019
Sep. 21, 2019
Jul. 26, 2019
May 31, 2019
Mar. 26, 2019
Jan. 18, 2019
Jan. 18, 2019
Dec. 02, 2018
Nov. 27, 2018
Jun. 04, 2018
Dec. 31, 2019
Dec. 31, 2018
Dec. 31, 2017
May 30, 2018
Number of common stock shares issued               2,005 3,334 1,500,000        
Proceeds from convertible notes [1]                     $ 2,603,750    
Warrants exercise price                           $ 6.00
Common stock par value                     $ 0.00001 $ 0.00001   $ 0.00001
New Employment Agreement [Member]                            
Annual base salary     $ 350,000                      
New Employment Agreement [Member] | Existing Options [Member]                            
Number of common stock shares issued     184,500                      
Common stock par value     $ 0.00001                      
Agreement description     In connection with entering into the New Employment Agreement, Dr. Glickman's existing one hundred and eighty four thousand five hundred (184,500) options ("Existing Options") to purchase Company common stock, $0.00001 par value per share (the "Common Stock") at ten dollars ($10.00) per share until October 1, 2026, were repriced to two dollars ($2.00) per share.                      
New Employment Agreement [Member] | New Options [Member]                            
Number of common stock shares issued     180,000                      
Agreement description     In connection to the New Employment Agreement shall be granted stock options ("New Options") for the right to purchase one hundred and eighty thousand (180,000) Common Stock at a price equal to two dollars ($2.00) per share exercisable until July 26, 2029, which shall vest quarterly over a three (3) year period, and shall be granted in accordance with the Hancock Jaffe 2016 Omnibus Incentive Plan (the "Option Plan"), and shall be subject to such other terms and conditions as are set forth in the Option Plan and the option agreement issued pursuant to the Option Plan.                      
Modification and excess fair value options vested     $ 20,295                      
Agreement term     3 years                      
Fair value of option grants     $ 28,800                      
Allen Boxer and Donna Mason [Member]                            
Proceeds from convertible notes                       $ 5,600,000 $ 5,600,000  
Number of restricted shares of common stock       157,000                    
Warrants term       5 years                    
Warrants to purchase of common stock       150,000                    
Warrants exercise price       $ 6.00                    
Hancock Jaffe Laboratory Aesthetics, Inc [Member]                            
Ownership percentage                     28.00%      
ATSCO, Inc [Member]                            
Payment on legal cost   $ 809,520       $ 810,055                
Payment for legal settlements           188,000                
Product liability contingency unasserted claims           $ 500,000                
Number of common stock shares issued   120,000                        
Litigation interest and legal costs seeking payment         $ 1,606,820                  
ATSCO, Inc [Member] | Hancock Jaffe Laboratory Aesthetics, Inc [Member]                            
Number of common stock shares issued             188,000              
Ownership percentage           28.00% 28.00%              
Gusrae Kaplan Nusbaum PLLC [Member]                            
Litigation interest and legal costs seeking payment $ 178,926                          
[1] Net of cash offering costs of $293,750.